Over 80% of breast cancer patients have ER-positive (ER+) tumours that express ER [2], and the androgen receptor (AR) is co-expressed with the estrogen receptor in 70–95% of all ER+ breast cancers [3, 4]. Here, AR is linked to neoplasm.